用机器学习来诊断和预测阿尔茨海默病中的脂蛋白和代谢物
Fenglin Wang1, Aimin Wang1, Yiming Huang1
1Department of Health Statistics, School of Public Health, Shandong Second Medical University, Weifang, Shandong, 261053, China.
Lipids in health and disease
|May 22, 2024
概括
年龄,IDL_PL_PCT和肌素等关键因素影响阿尔茨海默病 (AD) 的发病. 监测脂蛋白和代谢物有助于早期AD诊断和预防策略.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 医疗信息学 医疗信息学
背景情况:
- 阿尔茨海默病 (AD) 是一种具有重大经济影响的重大神经退行性疾病.
- 对阿尔茨海默病的预测模型存在,但关键影响因素仍然难以捉摸.
- 这项研究的重点是确定AD发病的关键脂蛋白和代谢物因素.
研究的目的:
- 通过机器学习分析影响阿尔茨海默病 (AD) 发病的关键脂蛋白和代谢因子.
- 为研究人员和医疗专业人员提供关于AD理解的见解.
- 为早期AD诊断,治疗和预防提供参考.
主要方法:
- 利用来自阿尔茨海默病神经成像计划 (ADNI) 数据库的603名参与者的数据 (对照组和AD患者).
- 采用随机森林,拉索回归和CatBoost算法来排名和过213个脂蛋白和代谢物变量.
- 构建了一个随机森林预测模型,包含了重要的变量,年龄,性别和婚姻状况.
主要成果:
- 选了14个脂蛋白和代谢物变量,其中17个被纳入最终的AD预测模型.
- 最优的随机森林模型实现了71.01%的准确性,79.59%的灵敏度和65.28%的特异性 (AUC:0.724).
- 最重要的预测变量包括年龄,中密度脂蛋白 (IDL_PL_PCT) 中的脂脂与总脂质的比率以及肌素.
结论:
- 年龄,IDL_PL_PCT和肌素是阿尔茨海默病 (AD) 发病的关键因素.
- 定期监测脂蛋白和代谢物对早期AD检测至关重要.
- 这些发现支持对AD的早期诊断和预防策略的改进.
更多相关视频
06:16Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
Published on: July 28, 2023
2.5K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
相关概念视频
Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
